No Data
Hua Green Biological (300970.SZ) announced a pre-loss, expecting a net loss of 38 million to -56 million yuan for the year 2024.
Hualu Biological (300970.SZ) announced that the company expects the net income attributable to Shareholders of the listed company for the year 2024 to be...
Hualu Biotech: 2024 Annual Performance Forecast
Jiangsu Chinagreen Biological Technology Group Co., Ltd. (SZSE:300970) Might Not Be As Mispriced As It Looks After Plunging 25%
Hua Lv Biotechnology (300970.SZ): has repurchased a total of 1.95% of its shares.
On December 31, Gelonghui reported that Hualü Biological (300970.SZ) announced that as of December 31, 2024, the company repurchased 2,346,600 shares through the Stock Exchange trading system in Shenzhen via centralized bidding, accounting for 1.95% of the company's current total share capital, with a highest Fill Price of 13.83 yuan/share, a lowest Fill Price of 12.22 yuan/share, and a total transaction amount of 30.0046 million yuan (excluding transaction fees).
Hualv Biological (300970.SZ): has repurchased a total of 2.3466 million shares.
Galonn announced on November 4th that Hualv Biology (300970.SZ) disclosed that as of October 31, 2024, the company repurchased 2.3466 million shares of the company through the Shenzhen Stock Exchange stock trading system through centralized bidding trading method, accounting for 1.95% of the current total share capital. The highest fill price was 13.83 yuan/share, the lowest fill price was 12.22 yuan/share, and the total fill amount was RMB 30.0046 million (excluding trading fees).
October 29th A-share investment lightning rod │ West Point Pharmaceutical: Shareholders Guotou High-Tech and Hangzhou Chuanghe plan to collectively reduce their shareholding by no more than 3%.
Observing Defense: Stocks may be subject to other risk warnings.